Agilent Technologies, Inc. (Santa Clara, California) Introduces Two New Screentape Assays To Optimize Next-Generation Sequencing Quality Control, Performance, Throughput

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced two new assays for the 2200 TapeStation system: the RNA ScreenTape and the D1000 ScreenTape assays. Both assays are essential for the quality control of samples in next-generation sequencing (NGS) workflow. They replace Agilent’s R6K and D1K ScreenTape assays.

Help employers find you! Check out all the jobs and post your resume.